Security: Series C Preferred
Location: Ottawa, ON

CEO: Imants Lauks

New Investors: Highland Capital Management
Existing Investors: Genesys Capital Partners

Board of Directors: Kelly Holman, Nathan Hukill, Kirk Mandy, Imants Lauks

-Epocal is a developer of the FDA 510(k) approved enterprise point-of-care blood diagnostic platform that delivers lab-quality results to the bedside at a significantly lower manufacturing cost than conventional point-of-care tests.

-Term sheet received one month after initiation of financing.